New research on SS-31 (elamipretide) shows the mitochondrial peptide increased ATP synthesis by 42% in laboratory studies. That data aligns with growing reports from users who say they notice energy improvements within their first week of treatment. (Journal of Biological Chemistry, September 2024)
SS-31 is designed to target cardiolipin, a specialized fat found in mitochondria's inner membrane. By stabilizing cardiolipin, the peptide helps mitochondria work more efficiently, which translates to better cellular energy production.
Clinical trials show consistent energy gains
The most recent clinical data comes from the TAZPOWER trial, which tracked patients with Barth syndrome for 168 weeks. Participants who received daily SS-31 injections sustained improvements in their six-minute walk test, adding an average of 96 meters to their walking distance. (Singh et al., March 2025)
That 25% improvement in walking capacity suggests the peptide's energy benefits go beyond just laboratory measurements. For people with mitochondrial dysfunction, being able to walk farther without fatigue represents a major quality-of-life change.
The FDA took notice. In September 2025, elamipretide became the first FDA-approved mitochondrial-targeted therapy, marketed under the brand name Forzinity. The approval covers Barth syndrome, but researchers are studying the peptide for other conditions involving mitochondrial dysfunction.
Why energy improvements happen quickly
Unlike many peptides that require weeks to show effects, SS-31 reaches high concentrations inside mitochondria within minutes of injection. That rapid uptake explains why some users report feeling more alert and energetic within days of starting treatment.
The peptide doesn't just boost energy production. It also reduces the production of reactive oxygen species (ROS), the cellular waste products that can damage mitochondria over time. By cutting ROS production while increasing ATP synthesis, SS-31 appears to improve both immediate energy levels and long-term mitochondrial health.
New derivatives show even stronger effects
Research published in September 2024 identified two new versions of SS-31 that outperformed the original peptide in laboratory tests. The compounds, designated 5f and 5g, reduced inflammatory markers by 43% and 45% respectively, compared to SS-31's anti-inflammatory effects. (RSC Advances, September 2024. PMID: 39284518)
Both derivatives also increased ATP production by about 41%, matching SS-31's energy-boosting effects while providing superior anti-inflammatory benefits. The researchers tested these compounds specifically on brain cells, suggesting potential applications for neurodegenerative diseases.
What the numbers don't capture
Clinical trials measure specific endpoints like walking distance or ATP levels in cell cultures. But user reports often describe broader changes: clearer thinking, better sleep, improved exercise tolerance. These subjective improvements are harder to measure but may reflect SS-31's systemic effects on cellular energy production.
The peptide's mechanism also suggests it could benefit anyone with age-related mitochondrial decline, not just people with diagnosed mitochondrial diseases. As we age, cardiolipin levels naturally decrease, and mitochondria become less efficient. SS-31's ability to stabilize cardiolipin could theoretically slow or reverse this process.
Limitations and ongoing questions
Most clinical data comes from people with severe mitochondrial disorders, not healthy individuals looking to boost energy. Whether SS-31 provides meaningful benefits to people with normal mitochondrial function remains unclear.
The peptide also requires daily injections, typically given subcutaneously at doses around 40 mg. That's a significant commitment for what might be modest energy improvements in otherwise healthy people.
Cost is another factor. As an FDA-approved drug for a rare disease, Forzinity carries a high price tag. Compounded versions are available but may not match the potency or purity of the pharmaceutical formulation.
What comes next for mitochondrial peptides
SS-31's FDA approval marks a turning point for mitochondrial medicine. Researchers are now testing the peptide for age-related macular degeneration, with Phase 3 results expected in late 2026.
The success of SS-31 has also sparked interest in other mitochondrial-targeting compounds. MOTS-C, another mitochondrial peptide, is entering clinical trials for metabolic disorders. The combination of SS-31 and MOTS-C is being studied for athletic performance, though data remains limited.
For now, SS-31 represents proof that targeting mitochondria directly can improve cellular energy production in humans. Whether that translates to meaningful benefits for healthy individuals will likely determine how widely these peptides are adopted beyond their current medical uses.
For more information on mitochondrial peptides, see our guides on SS-31 and MOTS-C.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide protocol.